Breast cancer is a malignant tumor originating in the breast tissue, classified into non-invasive and invasive types, with the latter further categorized into hormone receptor-positive, HER2-positive, and triple-negative subtypes based on molecular markers. It is the most common cancer among women globally and ranks second in cancer-related mortality.
Each year, an estimated 2.3 million new cases of breast cancer are diagnosed globally, with approximately 670,000 deaths. Incidence rates continue to rise in many regions, underscoring the urgent need for accessible, high-quality breast care—from screening and diagnosis to surgery, reconstruction, and survivorship support.
China accounts for approximately 17% of global breast cancer cases, with over 420,000 new cases annually. This substantial patient volume has endowed Fosun Health's clinical teams with unparalleled experience in managing complex breast cancer cases—from breast-conserving surgery for early-stage tumors to neoadjuvant therapy for locally advanced disease, and from targeted therapy for rare mutations to comprehensive rehabilitation. "The more we treat, the more precisely we cure."
Every breast cancer program has surgery, drugs, and radiation. Here is what makes ours different—and why patients from across the region choose Fosun Health:
"I have a small tumor. Can you destroy it without removing my breast or changing how it looks?"
The challenge: For many women, the fear of losing a breast—or waking up to a disfigured chest—is as overwhelming as the cancer itself. Even lumpectomy can leave visible deformity. And for some patients, surgery of any kind is not the best or only answer.
Our answer: Two pathways, both designed around a single principle—the cancer goes; the breast stays.
Pathway A: Organ-Sparing Ablation For carefully selected patients with small, localized tumors or isolated chest wall recurrences, image-guided precision ablation (radiofrequency, microwave, or cryoablation) destroys the tumor through a tiny puncture with millimeter accuracy—the breast remains completely intact. No large incisions. No removal of breast tissue. No change in breast shape. Combined with sentinel lymph node assessment, this offers a true organ-preserving alternative for those who decline or cannot tolerate conventional surgery.
Pathway B: Oncoplastic & Robotic Surgery When excision is necessary, our surgeons perform oncoplastic breast-conserving surgery—removing the cancer while immediately reshaping the breast for optimal aesthetic outcome. For patients requiring mastectomy, we offer nipple-sparing mastectomy with immediate implant or autologous reconstruction, preserving the breast skin envelope and nipple-areola complex. Where robotic precision adds value, 10× magnified 3D vision and tremor-free wristed instruments enable sub-millimeter navigation that maximizes tissue preservation.
- Early-stage: Remove the cancer, leave a breast that looks natural—or destroy it through a pinhole without removing any tissue at all.
- Mastectomy cases: Wake up with a reconstructed breast already in place.
What this means for you: Whether your tumor is best addressed by needle ablation or precision excision with immediate reconstruction, cancer removal and cosmetic preservation are planned as one integrated procedure—from the very first consultation.
"My cancer has returned in the chest wall, or a few spots have appeared in my bones or lungs. Do I need another major surgery?"
The challenge: Local recurrence or isolated metastases to bone or lung threaten your treatment course and quality of life. Major surgery means more trauma, longer recovery, and potential interruption to ongoing systemic therapy.
Our answer: CyberKnife M6 delivers 0.1mm sub-millimeter stereotactic radiosurgery, tracking tumor motion in real time and converging radiation from thousands of angles. It precisely ablates postoperative chest wall recurrences, lymph node relapses, or bone/lung oligometastases.
Because the procedure is completely non-invasive, there is no surgical trauma, no bleeding, no interruption to your ongoing systemic therapy. Your heart and lungs receive almost no radiation dose—making it uniquely safe for left-sided breast lesions.
- Recurrence: 1–5 outpatient sessions eliminate isolated recurrence sites.
- Oligometastases: Bone or lung spots ablated without a single incision—while you stay on your systemic treatment plan.
What this means for you: Recurrence does not automatically mean another operation. CyberKnife eliminates isolated sites and keeps you on your treatment plan without interruption.
"My HER2-positive cancer is becoming resistant. I have triple-negative disease. Can I afford years of treatment?"
The challenge: HER2-positive cancers develop resistance. Triple-negative cancers have limited targeted options. Hormone receptor-positive cancers require years of therapy. When standard drugs fail, the next line may not yet be available—or financially out of reach.
Our answer: In China, the next line comes sooner and costs less:
- HER2-positive / HER2-low: Trastuzumab deruxtecan (T-DXd / DS-8201)—unprecedented response rates in previously treated disease. HER2-directed bispecific antibodies for resistant cases.
- Hormone receptor-positive: CDK4/6 inhibitors + endocrine therapy—extending survival far beyond chemotherapy, with deep experience in long-term management.
- Triple-negative (TNBC): PD-1/PD-L1 inhibitors + chemotherapy—transforming outcomes for this historically difficult subtype.
- Cost advantage: Because these therapies are developed and manufactured within China's ecosystem, comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality.
Guided by NGS profiling and physicians who have managed thousands of resistance cases with these exact drugs.
What this means for you: Your resistance profile is matched to the right next-line drug sooner—at a cost that makes long-term treatment sustainable.
"How will I manage lymphedema after axillary surgery? Will I be strong enough to finish every chemotherapy cycle?"
The challenge: Breast cancer treatment spans months or years. Axillary lymph node surgery can cause lymphedema—painful, chronic arm swelling that affects mobility and quality of life for years. Chemotherapy, radiation, and targeted therapy deplete your strength. Many patients cannot complete their full planned course.
Our answer: Our integrative TCM program operates alongside your primary treatment as a "lymphatic and immune support system":
Toxicity Reduction: Evidence-informed herbal formulations protect organ function, ease chemotherapy-induced nausea and vomiting, relieve cancer-related fatigue, and reduce myelosuppression risk. Specialized acupuncture and herbal protocols directly target lymphedema prevention and management—addressing fluid stagnation, promoting lymphatic circulation, and reducing post-surgical swelling before it becomes chronic.
Efficacy Enhancement: Selected standardized preparations may improve tumor sensitivity to chemotherapy or targeted agents, supporting better disease control.
Acupuncture provides additional support for post-surgical pain, nausea, and fatigue. The goal: reduce treatment burden, protect your immune and lymphatic function, and keep you strong enough to complete every planned cycle—on schedule.
What this means for you: You do not have to choose between enduring treatment and maintaining your quality of life. Our integrated approach targets the side effects that most often force women off schedule—lymphedema, fatigue, nausea, low blood counts—so you can complete your full therapeutic course as planned.
Clinical Trial Fast-Track When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Every breast cancer case at Fosun Health is reviewed by a panel comprising breast surgery, medical oncology, radiation oncology, plastic/reconstructive surgery, radiology, and pathology specialists. This is essential because breast cancer decisions are uniquely complex: breast conservation versus mastectomy, immediate versus delayed reconstruction, neoadjuvant versus upfront surgery, endocrine sequencing, fertility preservation for younger patients—these choices require simultaneous input from multiple disciplines.
The MDT convenes within 48 hours of complete documentation. Your treatment plan is not a departmental preference. It is a consensus decision optimized for your cancer biology, your priorities, and your life circumstances.
In early 2023, Maya (a pseudonym), a 60-year-old patient, was eventually diagnosed with "Stage IIA invasive breast cancer".
Director Han Liangfu, Chief Medical Expert at Fosun Health Oncology Center (second from right), Director Zheng Dengrui (second from left), and Head Nurse Cai Yueying (first from left) during a patient ward round.
She moved between three different hospitals, before finally deciding to undergo follow-up treatment at the Fosun Chancheng Hospital Oncology Center in Foshan.
The team led by Director Han Liangfu designed a comprehensive treatment plan tailored specifically for Maya: 4 cycles of TC chemotherapy + 19 radiotherapy sessions + 5-10 years of endocrine therapy.
After chemotherapy, she was thankful not to experience vomiting as a side effect; during radiotherapy, she also avoided the awkward situation of having to undress. Furthermore, the medical team provided a 24-hour active online discussion group, answering her various questions and helping to alleviate her anxiety.
As her physical condition recovered, Maya undergoes regular check-ups, maintains an orderly lifestyle, and appears full of vitality.
Maya, dressed in red, appears in excellent condition, not looking at all like someone who was once a breast cancer patient.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your mammogram, ultrasound, MRI images, or pathology report. Our multidisciplinary breast team will provide a preliminary treatment plan and surgical recommendation within 48 hours.
